Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lyrica Will Be Available In Fall, Pfizer Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer announces approval of the third indication for Lyrica (pregabalin) on the same day that comments are due on the Drug Enforcement Agency’s proposed scheduling for the product. The Neurontin follow-on will launch with three out of four original indications.

You may also be interested in...



Pfizer Launches Lyrica Nine Months After First Approval

Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.

Pfizer Launches Lyrica Nine Months After First Approval

Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.

Lyrica Controlled Substance Scheduling Finalized By DEA

Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel